Cited by 191Adipose Tissue and MetabolismAdipokines, Inflammation, and Metabolic DiseasesPharmacology and Obesity Treatment

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective beta3-adrenoceptor agonist in humans.

Weyer, C, Tataranni, P A, Snitker, S, Danforth, E, Ravussin, E·1998·Diabetes

DOI 10.2337/diabetes.47.10.1555

Open this paper in CoChat — free account

Abstract

Stimulation of beta3-adrenoceptors by selective agonists improves insulin action and stimulates energy metabolism in various rodent models of obesity and type 2 diabetes. Whether selective beta3-adrenoceptor stimulation exerts metabolic actions in humans remains to be proven. The effects of a highly selective beta3-adrenoceptor agonist on insulin action, energy metabolism, and body composition were assessed in 14 healthy young lean male volunteers (age 22.5 +/- 3.3 years, 15 +/- 5% body fat [mean +/- SD]) randomly assigned to 8 weeks of treatment with either 1,500 mg/day of CL 316,243 (n = 10) or placebo (n = 4). Insulin-mediated glucose disposal (IMGD), nonoxidative glucose disposal (NOGD), oxidative glucose disposal (OGD) (indirect calorimetry), and splanchnic glucose output (SGO; beta3-[H3]glucose) were determined during a 100-min hyperinsulinemic-euglycemic glucose clamp (40 mU x m(-2) x min(-1)) before and after 4 and 8 weeks of treatment. The 24-h energy expenditure (24-EE), 24-h respiratory quotient (24-RQ), and the oxidation rates of fat and carbohydrate were determined in a respiratory chamber before and after 8 weeks. After 4 weeks, treatment with CL 316,243 increased IMGD (+45%, P < 0.01) in a plasma concentration-dependent manner (r = 0.76, P < 0.02). This effect was due to an 82% increase in NOGD (P < 0.01), while OGD and SGO remained unchanged. The effects on insulin action were markedly diminished after 8 weeks; this was significantly related to an unexpected decline in the plasma concentrations of CL 316,243 (-36%, P = 0.08). At this time, 24-RQ was lowered (P < 0.001), corresponding to a 23% increase in fat oxidation (P < 0.01) and a 17% decrease in carbohydrate oxidation (P = 0.05). The 24-EE after 8 weeks did not differ from baseline, and there was no change in body weight or body composition. Plasma concentrations of glucose, insulin, and leptin were unaffected by treatment, while free fatty acid concentrations increased by 41% (P < 0.05), again linearly with the achieved plasma concentration of CL 316,243 (r = 0.67, P < 0.05). Treatment with CL 316,243 had no effect on heart rate or blood pressure and caused no cases of tremors. We conclude that treatment of lean male subjects with CL 316,243 increases insulin action and fat oxidation, both in a plasma concentration-dependent manner. This is the first study to demonstrate unequivocal metabolic effects of a highly selective beta3-adrenoceptor agonist in humans.

Integrity signals

Registry

Crossref · 10.2337/diabetes.47.10.1555

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

INFLUENCES OF GLUCOSE LOADING AND OF INJECTED INSULIN ON HEPATIC GLUCOSE OUTPUT*
Steele, R. D. (1959) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1959.tb44923.x · Cited by 1,680
Uncoupling Protein-3 Is a Mediator of Thermogenesis Regulated by Thyroid Hormone, β3-Adrenergic Agonists, and Leptin
Gong, D., He, Y., Karas, M., & Reitman, M. L. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.39.24129 · Cited by 740
Activation of β3 Adrenergic Receptors Suppresses Leptin Expression and Mediates a Leptin-Independent Inhibition of Food Intake in Mice
Mantzoros, C. S., Frederich, R. C., Flier, J. S., Qu, D., Susulic, V. S., Lowell, B. B., & Maratos–Flier, E. (1996) · Diabetes · doi:10.2337/diab.45.7.909 · Cited by 314
Anti-obesity and anti-diabetic effects of CL 316, 243, a highly specific β3-adrenoceptor agonist, in yellow KK mice
Yoshida, T., Sakane, N., Wakabayashi, Y., Umekawa, T., & Kondo, M. (1994) · Life Sciences · doi:10.1016/0024-3205(94)00408-0 · Cited by 107
CL-316,243, a beta3-specific adrenoceptor agonist, enhances insulin-stimulated glucose disposal in nonobese rats
de Souza, C. J., Hirshman, M. F., & Horton, E. S. (1997) · Diabetes · doi:10.2337/diab.46.8.1257 · Cited by 95
Thermogenic and antiobesity activity of a novel β-adrenoceptor agonist (BRL 26830A) in mice and rats
Arch, J., & Ainsworth, A. T. (1983) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/38.4.549 · Cited by 74
Two-week stimulation or blockade of the sympathetic nervous system in man: Influence on body weight, body composition, and twenty four-hour energy expenditure
Acheson, K. J., Ravussin, É., Schoeller, D. A., Christin, L., Bourquin, L. D., Baertschi, P., Danforth, E., & Jéquier, E. (1988) · Metabolism · doi:10.1016/0026-0495(88)90035-2 · Cited by 65
Self-citation
Lack of beta 3-adrenergic effect on lipolysis in human subcutaneous adipose tissue
ROSENBAUM, M. S., Malbon, C. C., Hirsch, J., & Leibel, R. L. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.77.2.8393882 · Cited by 63
Treatment of obesity with thermogenic beta-adrenoceptor agonists: studies on BRL 26830A in rodents.
Arch, J. R. S., Ainsworth, A. T., Ellis, R. D., Piercy, V., Thody, V. E., Thurlby, P. L., Wilson, C., Wilson, S., & Young, P. (1984) · PubMed · Cited by 63
Antidiabetic and antiobesity effects of a highly selective β3‐adrenoceptor agonist (CL 316,243)
Largis, E. E., Burns, M. G., Muenkel, H. A., Dolan, J. A., & Claus, T. H. (1994) · Drug Development Research · doi:10.1002/ddr.430320203 · Cited by 45

Show all 13 references

Sorted by citations

Obesity and insulin resistance
Kahn, B. B., & Flier, J. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10842 · Cited by 3,345
Activation of Human Brown Adipose Tissue by a β3-Adrenergic Receptor Agonist
Cypess, A. M., Weiner, L. S., Roberts‐Toler, C., Franquet, E., Kessler, S., Kahn, P. A., English, J., Chatman, K., Trauger, S. A., Doria, A., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2014.12.009 · Cited by 1,053
Mice overexpressing human uncoupling protein-3 in skeletal muscle are hyperphagic and lean
Clapham, J. C., Arch, J. R. S., Chapman, H., Haynes, A., Lister, C., Moore, G. B. T., Piercy, V., Carter, S. A., Lehner, I., Smith, S. A., et al. (2000) · Nature · doi:10.1038/35019082 · Cited by 604
Cellular bioenergetics as a target for obesity therapy
Tseng, Y.-H., Cypess, A. M., & Kahn, C. R. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3138 · Cited by 591
New insights into sympathetic regulation of glucose and fat metabolism
Nonogaki, K. (2000) · Diabetologia · doi:10.1007/s001250051341 · Cited by 589
Increased Fat Intake, Impaired Fat Oxidation, and Failure of Fat Cell Proliferation Result in Ectopic Fat Storage, Insulin Resistance, and Type 2 Diabetes Mellitus
Ravussin, É., & Smith, S. R. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04292.x · Cited by 466
Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus
Heilbronn, L. K., Smith, S. R., & Ravussin, É. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802853 · Cited by 416
Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity
O’Mara, A. E., Johnson, J. W., Linderman, J. D., Brychta, R. J., McGehee, S., Fletcher, L. A., Fink, Y. A., Kapuria, D., Cassimatis, T. M., Kelsey, N., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131126 · Cited by 384
Brown fat as a therapy for obesity and diabetes
Cypess, A. M., & Kahn, C. R. (2010) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e328337a81f · Cited by 376
Adipose tissue lipolysis as a metabolic pathway to define pharmacological strategies against obesity and the metabolic syndrome
Langin, D. (2006) · Pharmacological Research · doi:10.1016/j.phrs.2006.03.009 · Cited by 359
Relationships between Rodent White Adipose Fat Pads and Human White Adipose Fat Depots
Chusyd, D. E., Wang, D., Huffman, D. M., & Nagy, T. R. (2016) · Frontiers in Nutrition · doi:10.3389/fnut.2016.00010 · Cited by 379
Current and Potential Drugs for Treatment of Obesity
Bray, G. A., & Greenway, F. L. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0383 · Cited by 327
Cold but not sympathomimetics activates human brown adipose tissue in vivo
Cypess, A. M., Chen, Y., Sze, C., Wang, K., English, J., Chan, O., Holman, A. R., Tal, I., Palmer, M. R., Kolodny, G. M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1207911109 · Cited by 312
Human Brown Adipose Tissue: What We Have Learned So Far
Betz, M. J., & Enerbäck, S. (2015) · Diabetes · doi:10.2337/db15-0146 · Cited by 223
β3-Adrenoceptor agonists: potential, pitfalls and progress
Arch, J. R. S. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01421-8 · Cited by 213
Differential Role of Adipose Tissues in Obesity and Related Metabolic and Vascular Complications
Gómez‐Hernández, A., Beneit, N., Díaz-Castroverde, S., & Escribano, Ó. (2016) · International Journal of Endocrinology · doi:10.1155/2016/1216783 · Cited by 211
Human adipose beiging in response to cold and mirabegron
Finlin, B. S., Memetimin, H., Confides, A. L., Kasza, I., Zhu, B., Vekaria, H. J., Harfmann, B. D., Jones, K. A., Johnson, Z., Westgate, P. M., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.121510 · Cited by 199
FAT CELLS: Afferent and Efferent Messages Define New Approaches to Treat Obesity
Lafontan, M. (2004) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095843 · Cited by 191
Markers of mitochondrial biogenesis and metabolism are lower in overweight and obese insulin-resistant subjects.
Heilbronn, L. K., Gan, S. K., Turner, N., Campbell, L. V., & Chisholm, D. J. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2210 · Cited by 184
Effect of a 28-d treatment with L-796568, a novel β3-adrenergic receptor agonist, on energy expenditure and body composition in obese men
Larsen, T. M., Toubro, S., van Baak, M. A., Gottesdiener, K. M., Larson, P., Saris, W. H., & Astrup, A. (2002) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/76.4.780 · Cited by 179
Brown adipose tissue and its therapeutic potential
Lidell, M. E., Betz, M. J., & Enerbäck, S. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12255 · Cited by 168
Role of Brown Fat in Lipoprotein Metabolism and Atherosclerosis
Hoeke, G., Kooijman, S., Boon, M. R., Rensen, P. C. N., & Berbée, J. F. P. (2016) · Circulation Research · doi:10.1161/circresaha.115.306647 · Cited by 166
The β3-adrenoceptor as a therapeutic target: Current perspectives
Ursino, M. G., Vasina, V. I., Raschi, E., Crema, F., & Ponti, F. D. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.01.002 · Cited by 161
‘Browning’ the cardiac and peri-vascular adipose tissues to modulate cardiovascular risk
Aldiss, P., Davies, G., Woods, R., Budge, H., Sacks, H. S., & Symonds, M. E. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.11.074 · Cited by 148
Adipose Tissue Fibrosis: Mechanisms, Models, and Importance
DeBari, M. K., & Abbott, R. D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176030 · Cited by 153
Regulation of Human Adipose Tissue Activation, Gallbladder Size, and Bile Acid Metabolism by a β3-Adrenergic Receptor Agonist
Baskin, A. S., Linderman, J. D., Brychta, R. J., McGehee, S., Anflick-Chames, E., Cero, C., Johnson, J. W., O’Mara, A. E., Fletcher, L. A., Leitner, B. P., et al. (2018) · Diabetes · doi:10.2337/db18-0462 · Cited by 145
Novel adipocyte lines from brown fat: A model system for the study of differentiation, energy metabolism, and insulin action
Klein, J. C., Faßhauer, M., Klein, H. H., Benito, M., & Kahn, C. R. (2002) · BioEssays · doi:10.1002/bies.10058 · Cited by 136
Fatty Acid Transport Protein 1 Is Required for Nonshivering Thermogenesis in Brown Adipose Tissue
Wu, Q., Kazantzis, M., Doege, H., Ortegon, A. M., Tsang, B., Falcon, A., & Stahl, A. (2006) · Diabetes · doi:10.2337/db06-0749 · Cited by 137
β-Adrenergic Receptors and Regulation of Energy Expenditure: A Family Affair
Robidoux, J., Martin, T. L., & Collins, S. (2004) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121659 · Cited by 132
Transdermal Delivery of Anti‐Obesity Compounds to Subcutaneous Adipose Tissue with Polymeric Microneedle Patches
Than, A., Liang, K., Xu, S., Sun, L., Duan, H., Xi, F., Xu, C., & Chen, P. (2017) · Small Methods · doi:10.1002/smtd.201700269 · Cited by 128
Small molecules for fat combustion: targeting obesity
Liu, J., Wang, Y., & Lin, L. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.09.007 · Cited by 125
Fat and carbohydrate balances during adaptation to a high-fat diet
Smith, S. R., de Jonge, L., Zachwieja, J. J., Roy, H. J., Nguyen, T., Rood, J. C., WINDHAUSER, M. M., & Bray, G. A. (2000) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/71.2.450 · Cited by 122
The role and importance of brown adipose tissue in energy homeostasis
Cypess, A. M., & Kahn, C. R. (2010) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e32833a8d6e · Cited by 129
Brown Adipose Tissue: Mechanisms and Potential Therapeutic Targets
Tam, C. S., Lecoultre, V., & Ravussin, E. (2012) · Circulation · doi:10.1161/circulationaha.111.042929 · Cited by 116
Control of fatty acid and glycerol release in adipose tissue lipolysis
Langin, D. (2006) · Comptes Rendus Biologies · doi:10.1016/j.crvi.2005.10.008 · Cited by 116
Anti-obesity drugs: a critical review of current therapies and future opportunities
Clapham, J. C. (2001) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(00)00105-4 · Cited by 111
HDAC11 suppresses the thermogenic program of adipose tissue via BRD2
Bagchi, R. A., Ferguson, B. S., Stratton, M. S., Hu, T., Cavasin, M. A., Sun, L., Lin, Y.-H., Liu, D., Londono, P., Song, K., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120159 · Cited by 110
Metabolic Circuit Involving Free Fatty Acids, microRNA 122, and Triglyceride Synthesis in Liver and Muscle Tissues
Chai, C., Rivkin, M., Berkovits, L., Simerzin, A., Zorde‐Khvalevsky, E., Rosenberg, N., Klein, S., Yaish, D., Durst, R. Y., Shpitzen, S., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.08.013 · Cited by 109
Regulation of glucose homoeostasis by brown adipose tissue
Peirce, V. J., & Vidal‐Puig, A. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70055-x · Cited by 111
Human Brown Adipose Tissue and Metabolic Health: Potential for Therapeutic Avenues
Singh, R., Barrios, A., Dirakvand, G., & Pervin, S. (2021) · Cells · doi:10.3390/cells10113030 · Cited by 114
Mechanical overload‐induced muscle‐derived extracellular vesicles promote adipose tissue lipolysis
Vechetti, I. J., Peck, B. D., Wen, Y., Walton, R. G., Valentino, T. R., Alimov, A. P., Dungan, C. M., Pelt, D. W. V., von Walden, F., Alkner, B. A., et al. (2021) · The FASEB Journal · doi:10.1096/fj.202100242r · Cited by 105
Acute effect of L‐796568, a novel β3‐adrenergic receptor agonist, on energy expenditure in obese men
van Baak, M. A., Hul, G. B. J., Toubro, S., Astrup, A., Gottesdiener, K. M., DeSmet, M., & Saris, W. H. M. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.122527 · Cited by 103
The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from β3-adrenoceptor agonists
Arch, J. R. S. (2008) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-008-0271-1 · Cited by 96
Lack of an Effect of a Novel β3-Adrenoceptor Agonist, TAK-677, on Energy Metabolism in Obese Individuals: A Double-Blind, Placebo-Controlled Randomized Study
Redman, L. M., de Jonge, L., Fang, X., Gamlin, B., Recker, D. P., Greenway, F. L., Smith, S. R., & Ravussin, É. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1740 · Cited by 92
Contribution of brown adipose tissue to human energy metabolism
Fernández‐Verdejo, R., Marlatt, K. L., Ravussin, É., & Galgani, J. E. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.07.003 · Cited by 85
Multiple obesity QTLs identified in an intercross between the NZO (New Zealand obese) and the SM (small) mouse strains
Taylor, B. A., Wnek, C., Schroeder, D. G., & Phillips, S. J. (2001) · Mammalian Genome · doi:10.1007/s003350010254 · Cited by 83
Concurrent physical activity increases fat oxidation during the shift to a high-fat diet
Smith, S. R., de Jonge, L., Zachwieja, J. J., Roy, H., Nguyen, T., Rood, J., Windhauser, M., Volaufova, J., & Bray, G. A. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/72.1.131 · Cited by 81
Brown adipose tissue: a potential target in the fight against obesity and the metabolic syndrome
Poekes, L., Lanthier, N., & Leclercq, I. A. (2015) · Clinical Science · doi:10.1042/cs20150339 · Cited by 83
Human beige adipocytes for drug discovery and cell therapy in metabolic diseases
Singh, A. M., Zhang, L., Avery, J. W., Yin, A., Du, Y., Wang, H., Li, Z., Fu, H., Yin, H., & Dalton, S. (2020) · Nature Communications · doi:10.1038/s41467-020-16340-3 · Cited by 78
Cooperative role of the glucagon‐like peptide‐1 receptor and β3‐adrenergic‐mediated signalling on fat mass reduction through the downregulation of PKA / AKT / AMPK signalling in the adipose tissue and muscle of rats
Decara, J. M., Rivera, P., Arrabal, S., Vargas, A., Serrano, A., Pavón, F. J., Diéguez, C., Nogueiras, R., de Fonseca, F. R., & Suárez, J. (2017) · Acta Physiologica · doi:10.1111/apha.13008 · Cited by 77
A Unique Population: Adipose-Resident Regulatory T Cells
Zeng, Q., Sun, X., Xiao, L., Xie, Z., Bettini, M., & Deng, T. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02075 · Cited by 75
New approaches in the pharmacological treatment of obesity
Leonhardt, M., Hrupka, B. J., & Langhans, W. (1999) · European Journal of Nutrition · doi:10.1007/s003940050040 · Cited by 65
Role of Human Brown Fat in Obesity, Metabolism and Cardiovascular Disease: Strategies to Turn Up the Heat
Ruiz, J. R., Martínez‐Téllez, B., Sánchez‐Delgado, G., Osuna‐Prieto, F. J., Rensen, P. C. N., & Boon, M. R. (2018) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2018.07.002 · Cited by 68
Adrenergic pathway activation enhances brown adipose tissue metabolism: A [18F]FDG PET/CT study in mice
Mirbolooki, M., Upadhyay, S. K., Constantinescu, C. C., Pan, M., & Mukherjee, J. (2013) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2013.08.009 · Cited by 64
Synthesis and Evaluation of Potent and Selective β3 Adrenergic Receptor Agonists Containing Acylsulfonamide, Sulfonylsulfonamide, and Sulfonylurea Carboxylic Acid Isosteres
Uehling, D., Donaldson, K. H., Deaton, D. N., Hyman, C. E., Sugg, E. E., Barrett, D. G., Hughes, R. G., Reitter, B. E., Adkison, K. K., Lancaster, M. E., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm0101500 · Cited by 63
Adipose tissue as source and target for novel therapies
Klein, J. C., Perwitz, N., Kraus, D., & Faßhauer, M. (2005) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2005.11.008 · Cited by 63
Artepillin C, a Typical Brazilian Propolis-Derived Component, Induces Brown-Like Adipocyte Formation in C3H10T1/2 Cells, Primary Inguinal White Adipose Tissue-Derived Adipocytes, and Mice
Nishikawa, S., Aoyama, H., Kamiya, M., Higuchi, J., Kato, A., Soga, M., Kawai, T., Yoshimura, K., Kumazawa, S., & Tsuda, T. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162512 · Cited by 63
Thermogenic Drugs as a Strategy for Treatment of Obesity
Astrup, A. V. (2000) · Endocrine · doi:10.1385/endo:13:2:207 · Cited by 57
Catecholamines suppress fatty acid re-esterification and increase oxidation in white adipocytes via STAT3
Reilly, S. M., Hung, C., Ahmadian, M., Zhao, P., Keinan, O., Gomez, A. V., DeLuca, J. H., Dadpey, B., Lu, D., Zaid, J., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0217-6 · Cited by 58
Whitening and Impaired Glucose Utilization of Brown Adipose Tissue in a Rat Model of Type 2 Diabetes Mellitus
Lapa, C., Arias-Loza, P.-A., Hayakawa, N., Wakabayashi, H., Werner, R. A., Chen, X., Shinaji, T., Herrmann, K., Pelzer, T., & Higuchi, T. (2017) · Scientific Reports · doi:10.1038/s41598-017-17148-w · Cited by 58
Increase in the Thermic Effect of Food in Women by Adrenergic Amines Extracted from Citrus Aurantium
Gougeon, R., Harrigan, K., Tremblay, J., Hedrei, P., Lamarche, M., & Morais, J. A. (2005) · Obesity Research · doi:10.1038/oby.2005.141 · Cited by 55
Detailed insight on β-adrenoceptors as therapeutic targets
Velmurugan, B. K., Baskaran, R., & Huang, C. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109039 · Cited by 54
Browning Epicardial Adipose Tissue: Friend or Foe?
Doukbi, E., Soghomonian, A., Sengenès, C., Ahmed, S., Ancel, P., Dutour, A., & Gaborit, B. (2022) · Cells · doi:10.3390/cells11060991 · Cited by 60
Effect of adipocyte β3-adrenergic receptor activation on the type 2 diabetic MKR mice
Kim, H., Pennisi, P. A., Gavrilova, O., Pack, S., Jou, W., Setser, J., East-Palmer, J., Tang, Y., Manganiello, V. C., & LeRoith, D. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00344.2005 · Cited by 55
Beta 3 adrenergic receptors: molecular, histological, functional and pharmacological approaches.
Coman, O. A., Păunescu, H., Ghiţă, I., Coman, L., Bădărăru, A., & Fulga, I. (2009) · PubMed · Cited by 53
β3-Adrenergic Receptor Stimulation Induces E-Selectin-mediated Adipose Tissue Inflammation
Flach, R. J. R., Matevossian, A., Akie, T. E., Negrin, K. A., Paul, M., & Czech, M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.412346 · Cited by 52
Adrenergic control of lipolysis in women compared with men
Schmidt, S. L., Bessesen, D. H., STOTZ, S. A., Peelor, F. F., Miller, B. F., & Horton, T. J. (2014) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00003.2014 · Cited by 51
Unlock the Thermogenic Potential of Adipose Tissue: Pharmacological Modulation and Implications for Treatment of Diabetes and Obesity
Peng, X., Gennemark, P., O’Mahony, G., & Bartesaghi, S. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00174 · Cited by 49
MECHANISMS IN ENDOCRINOLOGY: Human brown adipose tissue as a therapeutic target: warming up or cooling down?
McNeill, B. T., Suchacki, K. J., & Stimson, R. H. (2021) · European Journal of Endocrinology · doi:10.1530/eje-20-1439 · Cited by 55
Influence of dietary fats on c-Fos-like immunoreactivity in mouse hypothalamus
Wang, H., Storlien, L. H., & Huang, X. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01927-7 · Cited by 48
Evidence for fatty acids mediating CL 316,243-induced reductions in blood glucose in mice
MacPherson, R. E. K., Castellani, L. N., Beaudoin, M., & Wright, D. C. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00287.2014 · Cited by 47
Autophagy in Adipocyte Browning: Emerging Drug Target for Intervention in Obesity
Ro, S., Jang, Y., Bae, J., Kim, I. M., Schaecher, C., & Shomo, Z. D. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00022 · Cited by 47
The role of brown and beige adipose tissue in glycaemic control
Klepac, K., Georgiadi, A., Tschöp, M. H., & Herzig, S. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.07.001 · Cited by 48
Studies on the anti-obesity activity of zinc-α2-glycoprotein in the rat
Russell, S. T., & Tisdale, M. J. (2010) · International Journal of Obesity · doi:10.1038/ijo.2010.193 · Cited by 43
Pharmacotherapy for the treatment of obesity
Sweeting, A., HOCKING, S. L., & Markovic, T. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.09.005 · Cited by 45
Calpain-10 Gene Polymorphism Is Associated with Reduced β3-Adrenoceptor Function in Human Fat Cells
Hoffstedt, J., Näslund, E. B., & Arner, P. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.7.8680 · Cited by 41
Insulin and the β3-Adrenoceptor Differentially Regulate Uncoupling Protein-1 Expression
Klein, J. C., Faßhauer, M., Benito, M., & Kahn, C. R. (2000) · Molecular Endocrinology · doi:10.1210/mend.14.6.0477 · Cited by 40
Reversible lysine fatty acylation of an anchoring protein mediates adipocyte adrenergic signaling
Bagchi, R. A., Robinson, E. L., Hu, T., Cao, J., Hong, J. Y., Tharp, C. A., Qasim, H., Gavin, K. M., Silva, J. P. D., Major, J. L., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2119678119 · Cited by 40
Berardinelli-Seip congenital lipodystrophy 2 regulates adipocyte lipolysis, browning, and energy balance in adult animals
Zhou, H., Lei, X., Benson, T. W., MINTZ, J. D., Xu, X., Harris, R. B. S., Weintraub, N. L., Wang, X., & Chen, W. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m060244 · Cited by 37
Classification of Therapeutic and Experimental Drugs for Brown Adipose Tissue Activation: Potential Treatment Strategies for Diabetes and Obesity
Mukherjee, J., Baranwal, A., & Schade, K. N. (2016) · Current Diabetes Reviews · doi:10.2174/1573399812666160517115450 · Cited by 37
The dark side of browning
Tamucci, K. A., Namwanje, M., Fan, L., & Qiang, L. (2017) · Protein & Cell · doi:10.1007/s13238-017-0434-2 · Cited by 39
Attenuation of haemodynamic, metabolic and energy expenditure responses to isoproterenol in patients with hypertension
Valentini, M., Julius, S., Palatini, P., Brook, R. D., Bard, R. L., Bisognano, J. D., & Kaciroti, N. (2004) · Journal of Hypertension · doi:10.1097/00004872-200410000-00024 · Cited by 36
Dietary Fat Subtypes and Obesity
Storlien, L. H., Huang, X., Lin, S., Xin, X., Wang, H. Q., & Else, P. L. (2000) · KARGER eBooks · doi:10.1159/000059778 · Cited by 36
Naturally occurring mutations in G protein-coupled receptors associated with obesity and type 2 diabetes mellitus
Liu, T., Ji, R.-L., & Tao, Y.-X. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108044 · Cited by 34
Emerging paradigms for understanding fatness and diabetes risk
Smith, S. R., & Ravussin, É. (2002) · Current Diabetes Reports · doi:10.1007/s11892-002-0087-1 · Cited by 34
A systems perspective on brown adipogenesis and metabolic activation
Pradhan, R., Zachara, M., & Deplancke, B. (2017) · Obesity Reviews · doi:10.1111/obr.12512 · Cited by 37
Physiology and pathophysiology of the β3-adrenergic receptor
Yang, L.-K., & Tao, Y. (2018) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2018.09.003 · Cited by 32
Repurposing beta-3 adrenergic receptor agonists for Alzheimer’s disease: beneficial effects in a mouse model
Tournissac, M., Vu, T.-M., Vrabic, N., Hozer, C., Tremblay, C., Mélançon, K., Planel, E., Pifferi, F., & Calon, F. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00842-3 · Cited by 34
Orally Bioavailable β3-Adrenergic Receptor Agonists as Potential Therapeutic Agents for Obesityand Type-II Diabetes
Hu, B., & Jennings, L. L. (2003) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(02)41005-3 · Cited by 32
Novel anti-obesity drugs
Proietto, J., Fam, B. C., Ainslie, D. A., & Thorburn, A. W. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.6.1317 · Cited by 32
Pharmacological Treatment of Obesity
Kabra, D. G., Kabra, U. D., Tschöp, M. H., & Hofmann, S. M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3492-4_14 · Cited by 32
Insulin sensitisation in the treatment of Type 2 diabetes
Tadayyon, M., & Smith, S. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.3.307 · Cited by 30
Obesity Pharmacotherapy: Current Perspectives and Future Directions
Misra, M. (2013) · Current Cardiology Reviews · doi:10.2174/157340313805076322 · Cited by 29
Birth weight and the Metabolic Syndrome: thrifty phenotype or thrifty genotype?
Stern, M. P., Bartley, M., Duggirala, R., & Bradshaw, B. (2000) · Diabetes/Metabolism Research and Reviews · doi:10.1002/(sici)1520-7560(200003/04)16:2 · Cited by 65
Improved Therapeutic Efficiency against Obesity through Transdermal Drug Delivery Using Microneedle Arrays
Xie, Y., Shao, R., Lin, Y., Wang, C., Tan, Y. C., Xie, W., & Sun, S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060827 · Cited by 28
Obesity: an epidemic in need of therapeutics
der Ploeg, L. H. T. V. (2000) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(00)00114-9 · Cited by 27
Translational Pharmacology and Physiology of Brown Adipose Tissue in Human Disease and Treatment
Larson, C. J. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_184 · Cited by 26
The acute effects of the thermogenic supplement Meltdown on energy expenditure, fat oxidation, and hemodynamic responses in young, healthy males
Jitomir, J., Nassar, E., Culbertson, J. Y., Moreillon, J., Buford, T. W., Hudson, G. M., Cooke, M. B., Kreider, R. B., & Willoughby, D. S. (2008) · Journal of the International Society of Sports Nutrition · doi:10.1186/1550-2783-5-23 · Cited by 25
Selectivity and Potency of Agonists for the Three Subtypes of Cloned Human β-Adrenoceptors Expressed in Chinese Hamster Ovary Cells
Yanagisawa, T., Sato, T., Yamada, H., Sukegawa, J., & Nunoki, K. (2000) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.192.181 · Cited by 25
Therapeutic prospects of metabolically active brown adipose tissue in humans
Betz, M. J. (2011) · Frontiers in Endocrinology · doi:10.3389/fendo.2011.00086 · Cited by 24

Authors: Weyer, C., Tataranni, P. A., Snitker, S., Danforth, E., & Ravussin, E.
Affiliations: National Institutes of Health (US)
Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona 85016, USA. cweyer@phx.niddk.nih.gov
ORCID: Snitker, S
Venue: Diabetes
Publisher: American Diabetes Association
Published: 1998-10-01
Volume: 47
Issue: 10
Pages: 1555-1561
ISSN: 0012-1797 (ISSN-L)
1939-327X
DOI: 10.2337/diabetes.47.10.1555
OpenAlex: W2090592868
Cited by: 188
References: 13
Citations by year: 2026: 2 · 2025: 2 · 2024: 2 · 2023: 7 · 2022: 8 · 2021: 8 · 2020: 6 · 2019: 9 · 2018: 8 · 2017: 9 · 2016: 12 · 2015: 12 · 2014: 6 · 2013: 4 · 2012: 5
FWCI: 7.36
Type: journal article
Language: en
Open access: closed
Locations: Diabetes (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords: CL316,243, beta3-adrenergic agonists, insulin action, insulin-stimulated glucose disposal, nonoxidative glucose disposal, fat oxidation, carbohydrate oxidation, respiratory quotient, energy expenditure, body composition, plasma drug concentration, type 2 diabetes, obesity, energy metabolism
MeSH terms: Adrenergic beta-Agonists, Adult, Blood Glucose, Body Composition, Body Weight, Dioxoles, Double-Blind Method, Energy Metabolism, Fatty Acids, Nonesterified, Humans, Insulin, Male, Oxidation-Reduction, Proteins, Glucose Clamp Technique, Leptin, Lipid Metabolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective beta3-adrenoceptor agonist in humans.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks